Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
Stealth BioTherapeutics, a Phase 3 biotech focused on rare diseases caused by mitochondrial dysfunction, raised $78 million by offering 6.5 million shares at $12, the low end of the range of $12 to $14. Stealth BioTherapeutics plans to list on the Nasdaq under...read more
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six...read more
Stealth BioTherapeutics, a Phase 3 biotech focused on mitochondrial dysfunction, announced terms for its IPO on Wednesday. The Newton, MA-based company plans to raise $81 million by offering 6.2 million ADSs at a price range of $12 to $14. Insiders...read more
US IPO Weekly Recap: Blue jeans are back as Levi's preps March IPO
Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
Stealth BioTherapeutics prices IPO at $12, the low end of the range
Stealth BioTherapeutics, a Phase 3 biotech focused on rare diseases caused by mitochondrial dysfunction, raised $78 million by offering 6.5 million shares at $12, the low end of the range of $12 to $14. Stealth BioTherapeutics plans to list on the Nasdaq under...read more
US IPO Week Ahead: On track for 7 IPOs, led by Virgin Trains USA
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six...read more
Mitochondrial dysfunction biotech Stealth BioTherapeutics sets terms for $81 million IPO
Stealth BioTherapeutics, a Phase 3 biotech focused on mitochondrial dysfunction, announced terms for its IPO on Wednesday. The Newton, MA-based company plans to raise $81 million by offering 6.2 million ADSs at a price range of $12 to $14. Insiders...read more